@article{32ff82bee9974592b58958ea0917ddf1,
title = "Reply: Frequency of inappropriate and nonrecommended prasugrel prescription: Great variations",
author = "Hira, \{Ravi S.\} and Kevin Kennedy and Mahboob Alam and Petersen, \{Laura A.\} and Ballantyne, \{Christie M.\} and Virani, \{Salim S.\}",
note = "Funding Information: Please note: The views expressed in this article are those of the authors and do not necessarily represent the views of the United States Department of Veterans Affairs. Dr. Alam is a member of the advisory board for AstraZeneca. Dr. Ballantyne has received grant and research support (all paid to institution, not individual) from Abbott , Amarin , Amgen , Eli Lilly , GlaxoSmithKline , Merck \& Co. , Novartis , Pfizer , Regeneron , Roche , Sanofi-Synthelabo , the National Institutes of Health , and the American Heart Association . Dr. Ballantyne is a consultant for Abbott, Aegerion, Amarin, Amgen, Cerenis, Esperion, Genzyme, Kowa, Merck \& Co., Novartis, Pfizer, Resverlogix, Regeneron, Roche, and Sanofi-Synthelabo. Dr. Virani has received grant and research support from the Department of Veterans Affairs Health Services Research and Development Career Development Award (09-028), the American Diabetes Association , and the American Heart Association . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",
year = "2014",
month = dec,
day = "9",
doi = "10.1016/j.jacc.2014.09.030",
language = "English (US)",
volume = "64",
pages = "2434--2435",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier Inc.",
number = "22",
}